{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:22Z","timestamp":1785283162364,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jdcr.2026.04.020","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:05:05Z","timestamp":1776755105000},"page":"212-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cocaine-associated plasma cell orificial mucositis (CAPCOM): An emerging entity"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7615-9056","authenticated-orcid":false,"given":"Priya Patel","family":"Housley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milbrey","family":"Parke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-0826","authenticated-orcid":false,"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.04.020_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/DAD.0000000000002684","article-title":"Cocaine-induced plasma cell orificial \u201cdermatomucositis\u201d: a more accurate descriptive term for a clearly dermatological entity","volume":"46","author":"Fernandez-Flores","year":"2024","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"10.1016\/j.jdcr.2026.04.020_bib2","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1111\/jdv.18619","article-title":"Cocaine-induced plasma cell orificial mucositis","volume":"37","author":"Udondo Gonz\u00e1lez Del T\u00e1nago","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.04.020_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamadermatol.2023.5692","article-title":"Retrospective case series of cocaine-associated plasma cell orificial mucositis","volume":"160","author":"Viedma-Martinez","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2026.04.020_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ad.2022.09.005","article-title":"Cutaneous and mucosal conditions associated with cocaine use","volume":"114","author":"S\u00e1nchez-Puigdollers","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"10.1016\/j.jdcr.2026.04.020_bib5","article-title":"Cocaine-induced granulomatosis with polyangiitis-an under-recognized condition","volume":"7","author":"Gill","year":"2023","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.jdcr.2026.04.020_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag072","article-title":"ANCA testing in real-world clinical practice: diagnostic performance and predictive value in a Spanish cohort","volume":"65","author":"Loureiro-Amigo","year":"2026","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.jdcr.2026.04.020_bib7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/ced.12207","article-title":"Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine","volume":"38","author":"Jim\u00e9nez-Gallo","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.04.020_bib8","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/RHU.0000000000000813","article-title":"Clinical profile of levamisole-adulterated cocaine-induced vasculitis\/vasculopathy: a 30-case series","volume":"25","author":"Mu\u00f1oz-Vahos","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jdcr.2026.04.020_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103505","article-title":"Vasculopathy and vasculitis associated with levamisole-adulterated cocaine: a systematic review","volume":"158","author":"Scoglio","year":"2026","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.jdcr.2026.04.020_bib10","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1007\/s00405-022-07290-1","article-title":"Distribution of cocaine-induced midline destructive lesions: systematic review and classification","volume":"279","author":"Nitro","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"9","key":"10.1016\/j.jdcr.2026.04.020_bib11","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.20479","article-title":"Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis","volume":"50","author":"Wiesner","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jdcr.2026.04.020_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/ijd.16214","article-title":"Cutaneous manifestations of ANCA-associated vasculitis: a retrospective review of 211 cases with emphasis on clinicopathologic correlation and ANCA status","volume":"62","author":"Shakshouk","year":"2023","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jdcr.2026.04.020_bib13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/ijd.16247","article-title":"Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation","volume":"61","author":"Gibson","year":"2022","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.04.020_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70215","article-title":"Misdiagnosis of ANCA-associated vasculitis in patients with cocaine\/levamisole-associated autoimmune syndrome and cocaine-induced midline destructive lesions: a case series","volume":"13","author":"Sunmboye","year":"2025","journal-title":"Immun Inflamm Dis"},{"issue":"2","key":"10.1016\/j.jdcr.2026.04.020_bib15","article-title":"Urine toxicology screening reduces misdiagnosis of cocaine-induced ANCA-positive disease as idiopathic granulomatosis with polyangiitis","volume":"9","author":"Bateman","year":"2025","journal-title":"Rheumatol Adv Pract"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:26:56Z","timestamp":1785281216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"alternative-id":["S2352512626002201"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.04.020","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cocaine-associated plasma cell orificial mucositis (CAPCOM): An emerging entity","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}